Posted by Michael Wonder on 24 Jul 2022
Rhythm Pharmaceuticals receives positive CHMP opinion for Imcivree (setmelanotide) for the treatment of obesity and control of hunger in patients with Bardet-Biedl syndrome
European Commission decision anticipated in fourth quarter of 2022.
Rhythm Pharmaceuticals today announced that the EMA's CHMP has adopted a positive opinion recommending to expand the current marketing authorisation for Imcivree (setmelanotide) to include the treatment of obesity and control of hunger in adult and paediatric patients 6 years of age and older with genetically confirmed Bardet-Biedl syndrome.
